Form 4: Celularity Inc. Director Richard J. Berman Reports Stock and Option Awards

Director Richard J. Berman reports the acquisition of restricted stock units and stock options in Celularity Inc.

Summary

• Richard J. Berman, a director of Celularity Inc., reported the acquisition of 67,416 restricted stock units (RSUs) and 84,746 stock options on December 19, 2024.
• The RSUs and stock options were granted under the Celularity Inc. 2021 Equity Incentive Plan.
• The RSUs represent the right to receive one share of the Issuer's Class A common stock.
• The RSUs and stock options vest and become exercisable on the earlier of the one-year anniversary of the grant date (December 19, 2024) or the next annual stockholder meeting, contingent upon continuous service with the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard equity grant to a director. It's neither particularly positive nor negative from an investment perspective.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Industry Context

This filing is a routine disclosure of equity-based compensation for a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity grants to directors are a standard practice across the biotechnology industry.
• The vesting schedule of one year or the next annual stockholder meeting is fairly typical.
• The specific amount of equity granted would need to be compared to peer companies of similar size and stage of development to assess its relative magnitude.

Stakeholder Impact

• The equity grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
• The grant could have a minor dilutive effect on existing shareholders.

Key Dates